British Drugs Giant AstraZeneca Pondering Stock Market Shift to the U.S.
Don't Miss TipRanks' Half-Year Sale
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
U.K. Restrictions
Chief Executive Sir Pascal Soriot, as reported by The Times, has spoken privately about his desire to leave the FTSE 100 behind and head stateside.
Soriot is said to be concerned about how quickly Europe is falling behind the U.S. and China when it comes to medicine innovation. He is also known to be frustrated by the restrictions on approvals of new drugs and treatments by the state-owned National Institute for Health and Care Excellence, or NICE – such as breast cancer drug Enhertu.
AstraZeneca is no stranger to the U.S., which accounts for over 40% of its $54 billion group revenues. It recently ramped up investment there both to escape tariff hits and as a move away from those U.K. and European restrictions.
London Loss
The loss of the firm, with a market value of around £160 billion, would be a major blow to the London stock market and will likely meet opposition from some shareholders and the U.K. government.
It would follow on the heels of other firms shifting their primary listings to the U.S., such as building materials supplier CRH (CRH).
'America is important to its growth strategy and it could become an even bigger cog in the wheel,' said Dan Coatsworth, investment analyst at AJ Bell. 'The CEO seems frustrated at the lack of financial support to open new laboratories and manufacturing facilities in Europe and might see a full U.S. stock listing as a stepping stone to receiving better treatment stateside.'
Is AZN a Good Stock to Buy Now?
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
40 minutes ago
- Miami Herald
Trump confirms US tariffs to start when July 9 deadline arrives
American tariffs on dozens of countries will come into effect next Wednesday as scheduled, although several deals could still be worked out before then, President Donald Trump confirmed Friday. 'They'll range in value from maybe 60% or 70% tariffs to 10% and 20% tariffs, but they're going to be starting to go out sometime tomorrow. We've done the final form, and it's basically going to explain what the countries are going to be paying in tariffs,' Trump told reporters after landing at Joint Base Andrews. Trump first announced the so-called reciprocal tariffs of different sizes in April before issuing a 90-day pause which expires on July 9. The levies are separate from a 10% 'baseline' U.S. tariff on all countries. Since then, U.S. officials have reached a deal with Britain and later agreed to a temporary trade truce with China to allow for further negotiation. Earlier this week, Trump announced a deal with Vietnam that will see the Southeast Asian country pay a 20% tariff on 'any and all goods.' He also said a deal with Japan seems 'unlikely' at this point. Malaysia, India and the European Union are among the more than 50 nations that have so far failed to reach an agreement with American negotiators. Trump said Friday, his administration will start sending letters immediately to every country that has yet to make a deal with the United States, informing it of the exact percentage it will pay when the tariffs kick in. Letters will continue until the pause ends next week. The tariffs are calculated using a formula that takes into account the trade imbalance between the trading partner and the United States. India faces a 26% tariff, while South Korea's rate is 25%. Japan's rate is slightly lower at 24% and European 20% against the 27 member states making up the European Union. Trump said Friday, smaller countries could expect to see their U.S. tariffs kick in last, with first payments scheduled for the start of August. 'It's a lot of money for the country, but we're giving them a bargain,' Trump told reporters Friday. European Union officials said this week they are not hopeful of reaching a comprehensive deal before the deadline. European Commission President Ursula von der Leyen called reaching such a deal over a short 90-day period 'impossible.' 'What we are aiming at is an agreement in principle,' Von der Leyen told reporters earlier this week, adding a framework deal was the best thing to aim for with less than a week remaining before the deadline. Copyright 2025 UPI News Corporation. All Rights Reserved.
Business Insider
an hour ago
- Business Insider
Europe's drone push exposes gaps in defense readiness
As the prospect of a renewed Russian threat looms over Europe's eastern flank, EU leaders are accepting that the continent is ill-prepared when it comes to the risk of future conflict. Last week, Andrius Kubilius, the European commissioner for defence and space, called for a sweeping ramp-up of drone production, urging EU nations to produce millions of drones a year by 2030. Ukraine delivered over 1.3 million drones to its military in 2024, highlighting the gap in Europe's preparedness. "The fact that European nations need to urgently rearm, and to do so in a way that is relevant to the threat from Russia, is not a new discovery," Keir Giles, senior consulting fellow at Chatham House, told Business Insider. "What's alarming is that it's being presented as news," he said, adding that this suggests the realization that rearmament is vital "still hasn't sunk in evenly across Europe." The war in Ukraine has demonstrated the transformative nature of drones in modern combat. From cheap first-person view drones to advanced loitering munitions and AI-guided strike systems, the war has pioneered new forms of drone warfare, with Ukraine often outmatching Russian capabilities in speed and creativity. Katja Bego, a senior research fellow at Chatham House, said that "Ukraine's remarkable success with drones has shown it is possible to rapidly ramp up production if the urgency is there. Europe is now learning these lessons." Currently, however, the EU is still far behind. Both Russia and Ukraine reportedly outproduce the entire EU bloc "by orders of magnitude," Bego warned. But it's clear that there is increasing interest from EU states to work with and import Ukrainian expertise and systems. "If European countries are serious about acquiring drones at the pace and scale that is being described, they must do so in and with Ukraine," Giles said. The latest push for mass drone manufacturing in Europe isn't just about meeting current threats. It's about leapfrogging into the technologies that will define future conflict. "Europe sees an opportunity to leapfrog," Bego said. "Smaller drones are much cheaper than a lot of traditional weapons and can be produced much more quickly." However, making the most of this moment requires more than just factories. "Getting to the scale of relevance for deterrence and defense is more than an issue of defense production," Skip Davis, a senior fellow at the Center for European Policy Analysis, told Business Insider. "It's about the ability to field prototypes, train operators, revise operational concepts, and integrate drones into logistics and manoeuvre formations," he said. "All of that requires a new mindset." That would involve deeper collaboration between militaries and agile, often non-traditional tech firms. Davis said that in the current environment, "many of the companies leading innovation are small startups or commercial companies not used to working with militaries." For Europe to succeed, he said it must grow more comfortable with experimentation and iteration. Compounding the urgency is the decreasing estimate of when Russia could be ready to attack a NATO country. The estimate of five years was what we were hearing this time last year, Giles said. "Since then, the timescale has continued to shrink — and the reduction in US support to Ukraine brings the time closer." This shortening horizon makes the EU's slow progress all the more dangerous. "Crash rearmament is feasible, if there is sufficient political will," Giles added. At the same time, experts warn that ramping up drone output is not a silver bullet. "Policymakers are at risk of seeing small agile drones as a panacea which will solve both their financial and manpower woes," Bego said. But "there is still a need for large platforms like jet fighters, too," she added. Meanwhile, Europe's vision of "strategic autonomy" in defense risks being undermined by its reliance on foreign tech. "A lot of critical components in drone manufacturing are still produced in China," Bego said. "Europe must diversify these supply chains or reproduce them within its own borders." With the clock ticking and Russian production accelerating, the EU's ambitious drone target looks ever more necessary, and could mark a pivotal moment in European defense.
Yahoo
an hour ago
- Yahoo
Modella AI and AstraZeneca link for cancer clinical development
Modella AI has signed a multi-year agreement with AstraZeneca to expedite AI-driven oncology clinical development. The partnership will give AstraZeneca access to Modella AI's multi-modal foundation models. The agreement will enable the use of Modella AI's latest models, with rich feature extraction from different types of data, to speed up clinical development across AstraZeneca's worldwide oncology portfolio. AstraZeneca oncology research and development (R&D) chief AI and data scientist Jorge Reis-Filho stated: 'At AstraZeneca, AI is integrated across every aspect of clinical development. 'Through the use of foundation models, combined with our unique datasets and AI expertise, we are confident in our strategy to accelerate development and increase the probabilities of success in our oncology clinical trials.' AstraZeneca will use Modella AI's platform for cancer research R&D capabilities to improve biomarker discovery and clinical development while enhancing patient outcomes. By integrating these advanced foundation models into its R&D pipeline, AstraZeneca seeks to enable data-driven discovery methods with increased speed. Modella AI CEO Jill Stefanelli stated: 'Foundation models are transforming precision medicine. They are the backbone of AI-powered biomedical discovery and mark the first step toward fully autonomous AI agents. 'Our state-of-the-art multimodal foundation models provide powerful features from different data types for downstream tasks. When integrated with AstraZeneca's research engine, they will have the potential to accelerate data-driven development and enable the development of new AI agents that can automate complex R&D workflows.' In June 2025, the US Food and Drug Administration (FDA) approved AstraZeneca and Daiichi Sankyo's Datroway (datopotamab deruxtecan) for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) that exhibits mutations in the epidermal growth factor receptor. "Modella AI and AstraZeneca link for cancer clinical development" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
